PADI4 Antibodies

Santa Cruz Biotechnology features a diverse variety of PADI4 monoclonal antibodies for research focused on understanding peptidylarginine deiminase type 4 (PADI4). PADI4 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). PADI4 is an enzyme responsible for the post-translational modification of proteins through citrullination, which can influence protein function and immune responses. Research has shown PADI4's involvement in various autoimmune diseases, particularly rheumatoid arthritis, making it a crucial target for understanding disease mechanisms and potential therapeutic interventions. The study of PADI4 continues to reveal important insights into cellular processes and human health implications. Researchers working with PADI4 can utilize specific conjugates including horseradish peroxidase (HRP), phycoerythrin (PE), and fluorescein isothiocyanate (FITC) for enhanced detection methods. Advanced research techniques and protocols have expanded our understanding of PADI4's role in cellular function and disease progression. Santa Cruz Biotechnology monoclonal antibodies support the scientific community's ongoing efforts to advance PADI4 research and contribute to breakthrough discoveries in immunology and autoimmune disease treatment.